Affordable Access

deepdyve-link
Publisher Website

[Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results].

Authors
  • Borghi, Claudio1
  • Filardi, Pasquale Perrone2
  • 1 Cattedra di Medicina Interna, Università degli Studi, Bologna.
  • 2 Dipartimento di Scienze Biomediche Avanzate, Università degli Studi "Federico II", Napoli.
Type
Published Article
Journal
Giornale italiano di cardiologia (2006)
Publication Date
Jan 01, 2015
Volume
16
Issue
7-8 Suppl 1
Identifiers
DOI: 10.1714/1972.21370
PMID: 26442834
Source
Medline
License
Unknown

Abstract

The impact of low density lipoprotein (LDL) cholesterol levels on cardiovascular risk has been extensively studied. Statins have been demonstrated to significantly reduce LDL cholesterol levels, contributing to cardiovascular risk reduction particularly in patients with high cardiovascular risk. However, low adherence to statin therapy, often due to adverse effects, has raised the need for new pharmacological approaches to combine with statin therapy in order to reach the target levels of LDL cholesterol. Ezetimibe is a selective inhibitor of Niemann-Pick C1-like 1 (NPC1L1) protein that regulates the cholesterol uptake from the small intestine into the enterocytes. Ezetimibe has been demonstrated to significantly reduce LDL cholesterol levels in combination with statins and recent trials support its role in reducing the risk of cardiovascular events.

Report this publication

Statistics

Seen <100 times